Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estimating potency for the Emax-model without attaining maximal effects.

R C Schoemaker1, J M van Gerven, A F Cohen

  • 1Centre for Human Drug Research, Leiden, The Netherlands. rs@chdr.nl

Journal of Pharmacokinetics and Biopharmaceutics
|April 17, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using machine learning techniques to characterize sleep-deprived driving behavior.

Traffic injury prevention·2021
Same author

Towards remote monitoring in pediatric care and clinical trials-Tolerability, repeatability and reference values of candidate digital endpoints derived from physical activity, heart rate and sleep in healthy children.

PloS one·2021
Same author

The use of machine learning improves the assessment of drug-induced driving behaviour.

Accident; analysis and prevention·2020
Same author

Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation.

Pharmacological reviews·2020
Same author

Correction to: Retinal oximetry and fractal analysis of capillary maps in sickle cell disease patients and matched healthy volunteers.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2019
Same author

Retinal oximetry and fractal analysis of capillary maps in sickle cell disease patients and matched healthy volunteers.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2019
Same journal

Integrated equation to evaluate accumulation profiles of drugs eliminated by Michaelis-Menten kinetics.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Applications of a recirculatory stochastic pharmacokinetic model: limitations of compartmental models.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Effect of plasma protein and tissue binding on the time course of drug concentration in plasma.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Pharmacokinetics of methotrexate in solid tumors.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations.

Journal of pharmacokinetics and biopharmaceutics·2010
See all related articles

This study introduces a new parameter, S0, to better characterize drug potency when concentration-effect curves lack a clear maximum. This addresses limitations in the Emax model for imprecise potency estimations, improving drug development insights.

Area of Science:

  • Pharmacology
  • Biostatistics

Background:

  • The Emax model is widely used to link drug concentrations to effects.
  • Concentration-effect relationships can deviate from linearity without reaching a maximum due to side effects.
  • Estimating Emax model parameters (EC50, Emax) is imprecise when a maximum effect is not observed.

Purpose of the Study:

  • To introduce a novel parameter (S0 = Emax/EC50) for characterizing drug potency.
  • To provide an adequate measure of potency even when concentration-effect curves do not clearly reach a maximum.
  • To address the imprecision in EC50 and Emax estimates in such scenarios.

Main Methods:

  • Introduction of a new parameter, S0, defined as the ratio of Emax to EC50.
  • Use of simulations to investigate the properties of the S0 parameter.

Related Experiment Videos

  • Illustration using published examples of concentration-effect relationships.

    • Main Results:

    • The S0 parameter adequately characterizes potency even without a clear maximum in the concentration-effect curve.
    • Simulations demonstrate the utility and nature of the S0 parameter.
    • Published examples validate the application of S0 in real-world scenarios.

    Conclusions:

    • The S0 parameter offers a robust solution for potency characterization when Emax model assumptions are not met.
    • This approach enhances the precision of potency estimation in drug development.
    • The S0 parameter provides valuable insights into concentration-effect dynamics, especially in the presence of limiting side effects.